Evidence map›Paper›PMID 28589404›Full record

ArticleAdvances in therapy2017

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.

Sandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, Ignacio Dei-Cas, César Maldonado-García, Elkin O Peñaranda, Luís Puig, Xiangyi Meng, Todd Fox, Adriana Guana

Abstract readPublished Erratum
In one paragraph

Article in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Sandra AdsitTCR Medical Corporation, San Diego, CA, USA. sadsit@therapeuticsinc.com.
Enrique Rivas ZaldivarDermos, Guatemala City, Guatemala.
Howard SofenUCLA School of Medicine, Los Angeles, CA, USA.
Ignacio Dei-CasHalitus, Buenos Aires, Argentina.
César Maldonado-GarcíaCentro Dermatológico "Dr. Ladislao de la Pascua", Mexico City, Mexico.
Elkin O PeñarandaRiesgo de Fractura S.A., Bogota, Colombia.
Luís PuigHospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Xiangyi MengNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Todd FoxNovartis Pharma AG, Basel, Switzerland.
Adriana GuanaNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID28589404
PMCPMC5504197

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.